Short answer: kisspeptin is the master switch at the top of the reproductive hormone system, and unlike most research peptides, it has been given to people in clinical research for over 15 years, mainly at Imperial College London. In those studies it was generally well tolerated, with few reported side effects. Its most notable clinical use is as a gentler “trigger” in IVF for women at high risk of ovarian hyperstimulation syndrome. The open questions are about repeated, unsupervised use: the body can become desensitized to constant kisspeptin, which can switch the system down instead of up.
What kisspeptin does
Kisspeptin is made in the hypothalamus. It stimulates GnRH neurons, which tell the pituitary to release LH and FSH, which in turn drive testosterone in men and the ovarian cycle in women. Mutations that disable kisspeptin signalling cause a failure to go through puberty, which is how its role was discovered in 2003. Research products usually contain kisspeptin-10, the shortest active fragment; most clinical work used the longer kisspeptin-54. For how it compares with drugs acting further down the same chain, see kisspeptin vs HCG vs PT-141.
What the human research shows
| Area | Finding |
|---|---|
| Healthy men and women | Single doses raise LH and, in men, testosterone, confirming it acts upstream |
| IVF trigger (kisspeptin-54) | Triggered egg maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS), with very low OHSS rates (Abbara et al., 2015) |
| Brain imaging | Enhanced activity in brain areas linked to sexual and emotional processing |
| Approved drug | None anywhere |
Side effects
Across the published clinical studies, kisspeptin has generally been well tolerated, with no consistent pattern of significant adverse effects. Most studies were short (single doses to a few weeks) and medically supervised. Reported issues are mainly mild injection-site reactions; some people describe flushing or headache. The theoretical risks come from what it does downstream: raising sex hormones affects mood, libido, skin and, in women, the cycle.
The desensitization problem
Important: in clinical studies, continuous or repeated high exposure to kisspeptin can desensitize its receptor, so LH release falls instead of rising. This is the same principle that makes some GnRH-based drugs shut down sex hormones. More is not necessarily stronger, and the effect of repeated, unsupervised use is unknown.
| Health Canada | Not authorized. Kisspeptin was among products seized from Canada Peptide in 2025. |
|---|---|
| WADA | Peptides that stimulate LH release in men are prohibited under S2. |
See TrueLabs Kisspeptin and its COA →
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
What are the side effects of kisspeptin?
In supervised clinical studies, kisspeptin has generally been well tolerated, with mainly mild injection-site reactions reported. Repeated high exposure can desensitize the system, and long-term effects have not been studied.
Does kisspeptin raise testosterone?
Single doses raise LH and testosterone in men. With continuous exposure, the response can fade because the receptor becomes desensitized.
What is the difference between kisspeptin-10 and kisspeptin-54?
Both activate the same receptor. Kisspeptin-10 is the shortest active fragment and acts briefly; kisspeptin-54 is the longer form used in most clinical research, including IVF studies.
Is kisspeptin used in IVF?
In research, kisspeptin-54 has been used to trigger egg maturation in women at high risk of ovarian hyperstimulation syndrome. It is not an approved IVF drug.
Is kisspeptin legal in Canada?
Kisspeptin is not authorized by Health Canada and was among products seized from Canada Peptide in 2025.
Related reading
References
- Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization therapy. J Clin Endocrinol Metab. 2015. PubMed
- Seminara SB, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003. PubMed
- Health Canada. Advisory RA-77807 (Canada Peptide), August 1, 2025. Recalls and Safety Alerts
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice. For fertility questions, talk to a fertility specialist.